Following the completion of a Master of Science by Research in Applied Statistics at the University of Melbourne in 2007, Diana joined the NHMRC Clinical Trials Centre based at the University of Sydney. She returned to Melbourne in 2012 where she took up a position at the Peter MacCallum Cancer Centre. Diana joined the Clinical Epidemiology and Biostatistics Unit (CEBU) at Murdoch Childrens at the end of 2014 to work with the Cardiac Surgery and Cardiology Research Teams at The Royal Children's Hospital.
She has extensive experience in clinical trials and the applying statistical methods in medical research and has had numerous teaching roles with the Biostatistics Collaboration of Australia (BCA) program and Master of Public Health at the School of Public Health at the University of Sydney.
Diana’s main role at CEBU is to provide statistical support for the Cardiac Surgery and Cardiology Research Teams at RCH.
- Fontan Registry
- Cardiovascular Phenotype in Children with Chronic Inflammatory Disease (CUPID)
- Immunological, inflammatory and cardiovascular function in Kawasaki disease, viral myocarditis and toxic shock syndrome
Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of oncology 2012. 23 (6), 1531-1536
Tebbutt NC, Murphy F, Zannino D, Wilson K, Cummins MM, Abdi E, Strickland AH, Lowenthal RM, Marx G, Karapetis C, Shannon J, Goldstein D, Nayagam SS, Blum R, Chantrill L, Simes RJ, Price TJ. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of oncology 2011. 22 (8), 1834-1838
Tebbutt NC, Wilson K, Gebski V, Cummins MM, Zannino D, Van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of Clinical Oncology 2010. 28 (19), 3191-3198
Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel GA, Wilcken NRC, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. Journal of Clinical Oncology 2011. 29 (34), 4498-4504
Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer J-C, Dixon P, Davis TME, Pardy C, Colman P, Keech A. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011. 54 (1), 32-43